Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
M.D. Anderson Cancer Center
Centre Oscar Lambret
Ocellaris Pharma, Inc.
Regeneron Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Transgene
Tempus AI
NiKang Therapeutics, Inc.
Cancer Trials Ireland
NuCana plc
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
Daiichi Sankyo
NRG Oncology
M.D. Anderson Cancer Center
Novartis
M.D. Anderson Cancer Center
NextCure, Inc.
Elevation Oncology
Kymab Limited
Chinese University of Hong Kong
NantBioScience, Inc.
Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC
NantCell, Inc.
Pfizer
Medikine, Inc.
OHSU Knight Cancer Institute
European Organisation for Research and Treatment of Cancer - EORTC
Leap Therapeutics, Inc.
pharmaand GmbH
Georgetown University
Fred Hutchinson Cancer Center
Nektar Therapeutics
The Netherlands Cancer Institute
University of Leeds
Medstar Health Research Institute
Shanghai Jiao Tong University School of Medicine
Montefiore Medical Center
G1 Therapeutics, Inc.
University of Maryland, Baltimore
Palleos Healthcare GmbH
British Columbia Cancer Agency
MedSIR
Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc.
Incyte Corporation
Novartis